In the paper by Guerrero et al. (1), 95% confidence intervals for sensitivity and specificity for the comparison of different methods of detection of human papillomavirus (HPV) are given. I should like to point out that the 95% confidence intervals given are based on large sample approximations and are therefore quite misleading when the numbers on which the estimates are based are small. For example, for all controls the sensitivity of ViraPap (VP) against Southern hybridization (SH) ( Table 8 of Guerrero et al.) arises from 1 positive result from a total of 14, giving a value of 1/14 ϭ 7% (Table 1 ).
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The 95% confidence interval is given as 0 to 21. However, by consulting the appropriate tables of reference 2, it can be seen that the correct confidence interval is 0.2, 33.9, rounded off to the first decimal place. It is not difficult to check that these values are correct.
Also, no confidence intervals are given for values of sensitivity and specificity when the estimated value is 0 or 100%. This may suggest to some readers that confidence intervals cannot be calculated in these situations. This is not so. For example, in the calculation of sensitivity and specificity of the SH method against PCR it can be deduced that the results given in Guerrero's Table 8 have arisen from the Table 2 of this letter. This shows a sensitivity for SH of 0/12 ϭ 0% and a specificity for SH of 7/7 ϭ 100%. From Geigy Scientific Tables (2) it follows that the 95% confidence interval for sensitivity is 0, 26.5 and that for specificity is 59.0, 100, rounded off to the first decimal place. Although these are effectively one-sided intervals, they are still useful as an indication of the variability of the measures considered.
A second point concerns the measurement of agreement between type-specific diagnosis by SH and that by PCR. On p. 2951 of Guerrero et al., a concordance (percentage agreement) of 86% when HPVs were typed by both tests was found. It might be more appropriate in this circumstance to calculate Cohen's Kappa () as a measure of chance-corrected agreement. This is a measure of agreement that ranges from 1, indicating perfect agreement, to a value of less than zero, with chance agreement corresponding to zero. If this is done, the resulting value for equals 0.48. Although this value can be shown to be significantly better than chance, it would usually be taken to indicate only fair agreement. Returning to the data in Guerrero's Table 5 on which the above results are based, note that a concordance between type-specific diagnosis for when HPVs were typed of 73.5% will arise on a chance basis alone.
On p. 2955 of Guerrero et al., the question of whether the presence of blood in the specimen will lead to false-negative results using VP is raised. Surely the right approach here would be to cross-tabulate the presence or absence of blood with a positive or negative result by the VP method. This could be repeated separately for results that were positive or negative according to the SH method. The comparison used on p. 2956 would appear to apply to examining the effect of the presence or absence of blood on finding a positive result by the SH method. In order to provide a reliable diagnosis for the presence and type of human papillomavirus (HPV) DNA in a case-control study of cervical cancer in Colombia and Spain, 926 cervical scrapes from female subjects were examined by ViraPap (VP) and Southern hybridization (SH), and 510 of these (263 cases and 247 controls) were also tested by polymerase chain reaction (PCR) using the HPV Li consensus primers. HPV DNA prevalence was much higher in cases than in controls by each of the three tests. There was complete agreement between the results of the three tests for 64.9%o of the 510 specimens; 53.5% were negative and 11.4% were positive (regardless of type) by all tests. An additional 29.0%o of the specimens were positive by PCR: 19.4% by PCR alone, 6.7% by PCR and VP, and 2.9%o by PCR and SH. SH and/or VP gave positive results for 6.0%o of the specimens for which the PCR finding was negative: 2.7% by SH alone, 2.5% by VP alone, and 0.8% by both VP and SH. When specimens which were positive by VP alone or only by SH at low-stringency conditions were excluded, PCR confirmed all but four specimens which were positive by other tests. The concordance between type-specffic diagnosis by SH and PCR was 86% when HPVs were typed in both tests. HPV-16 accounted for over 80%o of the typed HPVs in each test. The presence of blood in case specimens did not appear to inhibit HPV positivity by VP or by PCR at the dilution tested. Low amounts of cellular DNA of specimens resulted in some underestimation of HPV positivity by VP and SH but not by PCR. Compared with that of PCR, the sensitivities for case specimens were 38% by SH and 50%o by VP; the sensitivity for control specimens, although it could not be measured precisely because there were few positive specimens, appeared to be lower than for case specimens. It was concluded that PCR-based tests are best suited for epidemiological investigation of HPVs.
The evidence linking genital tract human papillomavirus (HPV) infections to cancer of the uterine cervix has been derived from clinical, epidemiologic, and pathogenetic studies, as well as from laboratory studies of the oncogenic potential of HPV types (12, 26) . Two major difficulties have been encountered in the interpretation of HPV virologic data in epidemiologic investigations. First, because of small sample size and potential bias in the selection of subjects in most of the studies, it has been difficult to compare results from different investigations (16) . Second, HPV diagnosis, which requires nucleic acid hybridization tests, has been made by using a wide variety of procedures, e.g., Southern hybridization (SH), filter in situ hybridization (25) , dot blot hybridization, and polymerase chain reaction (PCR) (14, 19, 24 34% disagreement (2) . In a comparison carried out by two laboratories, the interlaboratory variation with filter in situ hybridization tests was even greater; 11 and 19% of specimens were positive with a mixed HPV-16 and HPV-18 probe in the two laboratories but only 3% were positive in both laboratories (17a, 18) . It has been suggested that errors in HPV identification rather than inadequacies of study design are the major source for discrepant results in epidemiological investigations of the HPV etiology of cervical cancer (6, 21 PCR amplification and hybridization. In order to minimize the possibility of contamination, aliquot-2 specimens from invasive cases and controls were processed for PCR in Lyon, France, in a laboratory which had not worked with HPV. Approximately one-half of the aliquot-2 specimen from each individual was digested with proteinase K (100 ,ug/ml) in a 125-,ul reaction at 55°C for 2 h in the presence of Nonidet P-40 (0.5%)-Tween 20 (0.5%). The sample tubes were then placed in a boiling water bath for 7 min (to inactivate the enzyme) and then centrifuged. The supernatants were distributed in 25-p,l aliquots and stored at -70°C.
Blank tubes (every 20th tube) and simian virus 40-transformed rat cells (every 10th tube) were processed with the specimens to monitor for contamination.
The processed specimens were transported to Baltimore, Md., for PCR amplification and HPV diagnosis. Amplification was performed taking precautions recommended to minimize the possibility of contamination (14) . HPV Li consensus primers (13) , which amplify an approximately 450-bp fragment of many HPV types, as well as ,-globin primers (19) which amplify a 260-bp sequence of the 13-globin gene, were included in the same tube. The final 100-pl PCR reaction mixture contained 5 p,l of the template, 50 mM KCl, 1% ME agarose; FMC Corporation, Rockland, Maine), visualized by ethidium bromide staining, and transferred by capillarity to nylon membranes. The filters were hybridized sequentially to end-labelled type-specific oligomer probes (19 to 22 bases) of HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, and HPV-35 and ,-globin (1) under highstringency conditions (Tm -15'C) for 1 h. Subsequent to the stringent hybridization with specific probes, the filters were screened with an HPV generic probe, which was a mixture of amplimers of HPV-16 and HPV-18. The amplimers for the generic probe were synthesized, as described previously (1), by using nested primer pairs, MY74 and MY75 for and MY76 and MY77 for HPV-18. This generic probe has been shown to be capable of detecting all the HPV types included in the VP, as well as many additional types, but it detects a narrower spectrum of HPVs than did the fouramplimer generic probe used by Bauer et al. (1, 13a men) and for 18 of 225 (8%) specimens which were negative by VP and SH.
The contribution of the different tests to the results for the 510 specimens (cases and controls combined) is shown in Fig. 2 . If specimens positive by VP alone or by SH alone are considered equivocal and excluded from analysis, then the PCR confirmed all but 4 (0.8%) of the 510 specimen results.
The degree of agreement between type-specific diagnoses by SH and PCR is shown in Table 5 . Among cases, typespecific diagnosis was made by both SH and PCR in 58 instances. For 50 of these cases (86%), the diagnoses were identical, and for an additional 5 cases, the types identified by the two tests, although different, were in the same subgroup of viruses (HPV-16, HPV-31, HPV-33, and HPV-35) known to be closely related (17) . In the remaining three instances, the specimens were identified as having HPV-16 by one test and HPV-18 by the other. There was little agreement between the classifications HPV-SH, unknown type and HPV-PCR, unknown type. Among specimens diagnosed as HPV-SH, unknown type, PCR was positive for The characteristics of the 31 specimens (12 cases and 19 controls) positive by VP or SH but not confirmed by PCR were as follows. Of the 12 case specimens, 5 were positive only by VP, 4 were positive only by SH at low stringency and 3 were positive by SH at high-stringency conditions as well as by VP. Of the 19 control specimens, 8 were positive by VP alone, 10 were positive only by SH at low-stringency conditions, and 1 was positive by VP as well as by SH at low-stringency conditions. Most of the specimens that were positive by SH but that were not confirmed by PCR were positive by SH only at low-stringency conditions. Multiple infections. In the analysis described above, specimens with multiple infections by SH (13 specimens) and by PCR (5 specimens) were counted as having only one HPV type; the specimen was considered to be positive for the type which was more prevalent in the study. All but four multiple infections were found in case specimens. The distribution of specimens positive for multiple types of HPV infections by SH was as follows: four for types 16 (Table 6) . A similar analysis was not conducted for control specimens because few of them were positive by VP or contained blood. Also, in our study, in which the original specimens were diluted 1:400 for PCR, the presence of blood in the original specimen seemed to have no demonstrable effect on P-globin amplification in case or control specimens. Among case specimens, 118 of 140 specimens (84.3%) with blood were positive for ,-globin compared with 139 of 162 specimens (85.8%) without blood. Among control specimens, 11 of 12 specimens (91.7%) with blood were positive for P-globin compared with 242 of 269 (90.0%) without blood. Relationship between 13-globin amplification and HPV positivity. The HPV positivity rate was higher for P-globinpositive case specimens (69% of 257 specimens) compared with 3-globin-negative case specimens (38% of 45 specimens) (P, <0.001). Similarly, for control specimens, HPV positivity in 3-globin-positive specimens (8.7% of 253 specimens) was greater than in P-globin-negative specimens (3.6% of 28 specimens), but this difference was not statistically significant (P = 0.3).
Amount of cellular DNA and HPV positivity. The amounts of cellular DNA were measured by spectrofluorometry for specimens which were tested by SH. The median amount and interquartile range of cellular DNA for 527 case specimens (1,850 ng and 560 to 5,760 ng, respectively) was significantly greater than those for 399 control specimens (1,100 ng and 320 to 2950 ng, respectively) (P, <0.001). Also, 28% of the case specimens, but only 14% of the control specimens, had greater than 5,000 ng of DNA (P, <0.0001). Therefore, we analyzed whether HPV positivity of case and control specimens was affected by the amount of cellular DNA ( Table 7 ). The amounts of cellular DNA used for SH and PCR were, respectively, 80 and 1% of those used for VP. Among case specimens, the proportions of specimens positive by VP and SH with the lowest amount (<100 ng) of cellular DNA were 19 and 9%, respectively; these values were significantly lower than those for specimens with higher amounts of DNA (P, <0.005 for VP and <0.001 for SH). For specimens with more than 100 ng of DNA, the HPV positivity rates for case specimens by VP did not increase significantly with increasing amounts of cellular DNA (P = 0.23), but they did for SH (P = 0.02). In contrast to these findings by VP and SH, the amount of cellular DNA did not influence the rate of HPV positivity by PCR. These results suggest that HPV positivity by VP and SH may have been underestimated for case specimens with low amounts of cellular DNA. There were few HPV-positive control specimens, but by both VP and SH, there was a significant trend of increasing HPV positivity with increasing amounts of specimen DNA. As with case specimens, the HPV positivity in control specimens by PCR was not affected by amounts of cellular DNA.
Sensitivity and specificity. In view of the effect of cellular DNA amount on HPV positivity by SH and VP, estimates of sensitivity and specificity were made after stratification by DNA amount. Only those specimens which were examined by all three tests were considered; VP was compared with SH and both VP and SH were compared with PCR. Estimates were made separately for cases and controls (Table 8) . For cases, VP had an identical overall value of 79% for both sensitivity and specificity against SH as the reference test; against PCR, both VP and SH showed high levels of specificity (87 to 100%), but at each cellular DNA amount category, VP had a higher sensitivity than SH, with an overall value of 50% for VP versus 38% for SH. Both VP and SH had low sensitivity for cellular DNA amounts of <100 ng. For controls, the estimated specificity was high (87 to 100%) in all comparisons. The estimate of sensitivity for controls was imprecise because few specimens were positive. Nevertheless, in all comparisons, sensitivity for controls was lower than that for cases, raising the possibility of differential misclassification.
DISCUSSION
The major goal of these studies was to provide reliable HPV diagnoses in the epidemiological investigation of cervical cancer in Colombia and Spain. In view of the known intra-and intertest variability of the diagnostic procedures, a large number of specimens from invasive carcinoma cases and controls were examined by each of three procedures: VP, which is commercially available; SH, which is considered the gold standard; and PCR, which is capable of detecting very small amounts of virus. The goal of providing a reliable HPV diagnosis was largely met. The differences in HPV prevalence rates between cases and controls were highly significant when judged by the results of any of the three tests individually or by any combination of the results of the three tests. The low HPV prevalence rate in controls was confirmed by all three tests. The predominance of HPV-16 and the relative paucity of HPV-18 were confirmed by both PCR and SH, the two tests capable of providing type-specific diagnosis. Thus, virologic examination of the specimens by three tests allowed a confident interpretation of the data in the case-control study (1Sa).
As expected, HPV detection rate was higher among 0-globin-positive specimens than among P-globin-negative specimens. In the test system, the HPV primer concentrations are higher than ,-globin primer concentrations so as to favor HPV amplification over 3-globin amplification (13a The inhibitory action of blood on PCR amplification is clearly established (10) . However, in our study, the blood contaminating the cervical scrapes appeared not to inhibit amplification probably because the specimens were diluted 1:400 prior to being tested. Since a significant proportion of the case specimens were bloody, the PCR component of the study would have been compromised if bloody specimens had to be excluded from analysis. Two additional commonly expressed concerns about PCR were not encountered in this study. First, in the numerous controls interspersed throughout the tests to monitor contamination, not a single instance of contamination was discovered. Second, the suspicion that HPV infections are so persistent and widespread that a highly sensitive technique like PCR will detect clinically irrelevant HPVs in a large number of controls was not borne out. The low HPV Table 3 for specimens examined by all three tests, the PCR positivity for cases that were positive by VP but negative by SH is higher than that for cases that were negative by both VP and SH (34 of 39 versus 81 of 147, P, <0.001), an indication that some of the specimens in this group may have been true positives missed by SH. Kiviat et al. (11) have reported a higher sensitivity and specificity (both greater than 90%) of VP, as measured against the gold standard of SH, than those estimated in our study. One reason for their higher values may be that they performed the two tests using identical reagents (including RNA probes), whereas we performed SH using DNA probes and reagents not identical with those in the VP kit.
In conclusion, the results of our study strongly imply that PCR-based HPV diagnosis is the method of choice for future epidemiological investigation. However, there is a strong need to validate and standardize reagents for PCR tests and to have one or more reference centers which can assist in quality control of the test. The results of PCR tests are heavily dependent on the choice of primers and probes (22) . It is necessary that different PCR protocols now in use (1, 8, 24) be compared with each other in tests of clinical specimens. Questions that need attention include the best way to process a cervical scrape sample for PCR, the comparability of amplification by consensus primers with that by typespecific primers, whether employment of more than one primer pair in the same reaction tube decreases the sensitivity of HPV detection, the differences in detection of HPV types by the different generic probes, validity of the typespecific diagnosis of PCR products with the oligomer probes, and development of reagents to identify HPVs which are now classified as unknown types. In addition to the PCRbased test, it would also be useful in future studies to test at least a subset of the specimens with a second test which is not amplification based and which can provide type-specific diagnosis as well as an estimate of the quantity of HPV in the sample. In this way, it will be possible to monitor the PCR-based diagnosis when both tests are positive and to evaluate the importance of virus load in distinguishing between cases and controls.
